PERSPECTIVES ON USE OF BEVACIZUMAB IN PATIENTS WITH NEUROENDOCRINE TUMORS. CASE REPORT

PERSPECTIVES ON USE OF BEVACIZUMAB IN PATIENTS WITH NEUROENDOCRINE TUMORS. CASE REPORT

Advanced well differentiated neuroendocrine tumors (NET) have poor sensitivity to chemotherapy. Biotherapy and targeted therapy are the main treatment options for these patients. Approaches to the 2nd and subsequent lines of treatment have not been developed to date. VEGFR blocker bevacizumab is act...

Full description

Bibliographic Details
Main Authors: G. S. Emelianova, N. F. Orel, V. A. Gorbunova, A. A. Kolomeytseva, A. A. Kuznetsova, A. E. Kuzminov, A. A. Fedenko
Format: Article
Language:Russian
Published: Tomsk National Research Medical Center of the Russian Academy of Sciences 2017-12-01
Series:Sibirskij Onkologičeskij Žurnal
Subjects:
neuroendocrine tumors
bevacizumab
Online Access:https://www.siboncoj.ru/jour/article/view/647
id doaj-c0f77ee0f2584480bb4c96f6dbc1ffcb
record_format Article
spelling doaj-c0f77ee0f2584480bb4c96f6dbc1ffcb2021-07-28T21:02:04ZrusTomsk National Research Medical Center of the Russian Academy of SciencesSibirskij Onkologičeskij Žurnal1814-48612312-31682017-12-0116610010410.21294/1814-4861-2017-16-6-100-104504PERSPECTIVES ON USE OF BEVACIZUMAB IN PATIENTS WITH NEUROENDOCRINE TUMORS. CASE REPORTG. S. Emelianova0N. F. Orel1V. A. Gorbunova2A. A. Kolomeytseva3A. A. Kuznetsova4A. E. Kuzminov5A. A. Fedenko6Moscow State University of Medicine and Dentistry, MoscowN.N. Blokhin Russian Cancer Research Center, Moscow; Russian Medical Academy of Continued Professional Education, MoscowN.N. Blokhin Russian Cancer Research Center, MoscowN.N. Blokhin Russian Cancer Research Center, MoscowN.N. Blokhin Russian Cancer Research Center, MoscowN.N. Blokhin Russian Cancer Research Center, MoscowN.N. Blokhin Russian Cancer Research Center, MoscowAdvanced well differentiated neuroendocrine tumors (NET) have poor sensitivity to chemotherapy. Biotherapy and targeted therapy are the main treatment options for these patients. Approaches to the 2nd and subsequent lines of treatment have not been developed to date. VEGFR blocker bevacizumab is actively studied in well differentiated NET. For well differentiated NET, it has been shown that an increase in VEGF expression is associated with metastasis and decrease in progression-free survival.https://www.siboncoj.ru/jour/article/view/647neuroendocrine tumorsbevacizumab
collection DOAJ
language Russian
format Article
sources DOAJ
author G. S. Emelianova
N. F. Orel
V. A. Gorbunova
A. A. Kolomeytseva
A. A. Kuznetsova
A. E. Kuzminov
A. A. Fedenko
spellingShingle G. S. Emelianova
N. F. Orel
V. A. Gorbunova
A. A. Kolomeytseva
A. A. Kuznetsova
A. E. Kuzminov
A. A. Fedenko
PERSPECTIVES ON USE OF BEVACIZUMAB IN PATIENTS WITH NEUROENDOCRINE TUMORS. CASE REPORT
Sibirskij Onkologičeskij Žurnal
neuroendocrine tumors
bevacizumab
author_facet G. S. Emelianova
N. F. Orel
V. A. Gorbunova
A. A. Kolomeytseva
A. A. Kuznetsova
A. E. Kuzminov
A. A. Fedenko
author_sort G. S. Emelianova
title PERSPECTIVES ON USE OF BEVACIZUMAB IN PATIENTS WITH NEUROENDOCRINE TUMORS. CASE REPORT
title_short PERSPECTIVES ON USE OF BEVACIZUMAB IN PATIENTS WITH NEUROENDOCRINE TUMORS. CASE REPORT
title_full PERSPECTIVES ON USE OF BEVACIZUMAB IN PATIENTS WITH NEUROENDOCRINE TUMORS. CASE REPORT
title_fullStr PERSPECTIVES ON USE OF BEVACIZUMAB IN PATIENTS WITH NEUROENDOCRINE TUMORS. CASE REPORT
title_full_unstemmed PERSPECTIVES ON USE OF BEVACIZUMAB IN PATIENTS WITH NEUROENDOCRINE TUMORS. CASE REPORT
title_sort perspectives on use of bevacizumab in patients with neuroendocrine tumors. case report
publisher Tomsk National Research Medical Center of the Russian Academy of Sciences
series Sibirskij Onkologičeskij Žurnal
issn 1814-4861
2312-3168
publishDate 2017-12-01
description Advanced well differentiated neuroendocrine tumors (NET) have poor sensitivity to chemotherapy. Biotherapy and targeted therapy are the main treatment options for these patients. Approaches to the 2nd and subsequent lines of treatment have not been developed to date. VEGFR blocker bevacizumab is actively studied in well differentiated NET. For well differentiated NET, it has been shown that an increase in VEGF expression is associated with metastasis and decrease in progression-free survival.
topic neuroendocrine tumors
bevacizumab
url https://www.siboncoj.ru/jour/article/view/647
work_keys_str_mv AT gsemelianova perspectivesonuseofbevacizumabinpatientswithneuroendocrinetumorscasereport
AT nforel perspectivesonuseofbevacizumabinpatientswithneuroendocrinetumorscasereport
AT vagorbunova perspectivesonuseofbevacizumabinpatientswithneuroendocrinetumorscasereport
AT aakolomeytseva perspectivesonuseofbevacizumabinpatientswithneuroendocrinetumorscasereport
AT aakuznetsova perspectivesonuseofbevacizumabinpatientswithneuroendocrinetumorscasereport
AT aekuzminov perspectivesonuseofbevacizumabinpatientswithneuroendocrinetumorscasereport
AT aafedenko perspectivesonuseofbevacizumabinpatientswithneuroendocrinetumorscasereport
_version_ 1721263270806945792

Similar Items